Literature DB >> 2568889

Structure of the gene of tum- transplantation antigen P91A: the mutated exon encodes a peptide recognized with Ld by cytolytic T cells.

C Lurquin1, A Van Pel, B Mariamé, E De Plaen, J P Szikora, C Janssens, M J Reddehase, J Lejeune, T Boon.   

Abstract

Mutagen treatment of mouse P815 tumor cells produces immunogenic mutants that express new transplantation antigens (tum- antigens) recognized by cytolytic T cells. We found that the gene conferring expression of tum- antigen P91A contains 12 exons, encoding a 60 kd protein lacking a typical N-terminal signal sequence. The sequence shows no significant similarity with sequences in current data bases. A mutation that causes expression of the antigen is located in exon 4; it is the only apparent difference between the normal and the antigenic alleles. A short synthetic peptide corresponding to a region of exon 4 located around this mutation makes P815 cells sensitive to lysis by anti-P91A cytolytic T cells. The mutation creates a strong aggretope enabling the peptide to bind the H-2 Ld molecule. Several secondary tumor cell variants that no longer express tum- antigen P91A were found to carry deletions in the gene.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2568889     DOI: 10.1016/0092-8674(89)90844-1

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  83 in total

1.  The immunoprotective MHC II epitope of a chemically induced tumor harbors a unique mutation in a ribosomal protein.

Authors:  T Matsutake; P K Srivastava
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-27       Impact factor: 11.205

Review 2.  Immunotherapy of melanoma.

Authors:  C Smith; V Cerundolo
Journal:  Immunology       Date:  2001-09       Impact factor: 7.397

3.  A new approach to the cloning of genes encoding T-cell epitopes.

Authors:  D M Scott; P J Dyson; E Simpson
Journal:  Immunogenetics       Date:  1992       Impact factor: 2.846

4.  Mapping of the genes encoding tum- transplantation antigens P91A, P35B, and P198.

Authors:  P J Dyson; C de Smet; A M Knight; D Simon-Chazottes; J L Guénet; T Boon
Journal:  Immunogenetics       Date:  1992       Impact factor: 2.846

Review 5.  Immune recognition of self in immunity against cancer.

Authors:  Alan N Houghton; José A Guevara-Patiño
Journal:  J Clin Invest       Date:  2004-08       Impact factor: 14.808

Review 6.  Role of major histocompatibility complex class-I molecules in tumor rejection. New insights from studies with synthetic peptides and transgenic mice.

Authors:  P Höglund; H G Ljunggren; K Kärre; G Jay
Journal:  Immunol Res       Date:  1990       Impact factor: 2.829

7.  Cognate peptides induce self-destruction of CD8+ cytolytic T lymphocytes.

Authors:  P R Walden; H N Eisen
Journal:  Proc Natl Acad Sci U S A       Date:  1990-11       Impact factor: 11.205

8.  Do we need a pepton hypothesis?

Authors:  K F Lindahl
Journal:  Immunogenetics       Date:  1991       Impact factor: 2.846

9.  Targeting the intratumoral dendritic cells by the oncolytic adenoviral vaccine expressing RANTES elicits potent antitumor immunity.

Authors:  Natalia Lapteva; Melissa Aldrich; David Weksberg; Lisa Rollins; Tatiana Goltsova; Si-Yi Chen; Xue F Huang
Journal:  J Immunother       Date:  2009 Feb-Mar       Impact factor: 4.456

10.  Efficient expression of tum- antigen P91A by transfected subgenic fragments.

Authors:  P Chomez; E De Plaen; A Van Pel; C De Smet; J P Szikora; C Lurquin; A M Lebacq-Verheyden; T Boon
Journal:  Immunogenetics       Date:  1992       Impact factor: 2.846

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.